In last trading session, Prothena Corporation plc (NASDAQ:PRTA) saw 0.52 million shares changing hands with its beta currently measuring 0.08. Company’s recent per share price level of $13.05 trading at -$1.11 or -7.84% at ring of the bell on the day assigns it a market valuation of $702.20M. That closing price of PRTA’s stock is at a discount of -218.31% from its 52-week high price of $41.54 and is indicating a premium of 10.34% from its 52-week low price of $11.70. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.52 million shares which gives us an average trading volume of 556.68K if we extend that period to 3-months.

For Prothena Corporation plc (PRTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 15 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.04 in the current quarter.

Prothena Corporation plc (NASDAQ:PRTA) trade information

Upright in the red during last session for losing -7.84%, in the last five days PRTA remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $13.05 price level, adding 9.81% to its value on the day. Prothena Corporation plc’s shares saw a change of -5.78% in year-to-date performance and have moved -4.54% in past 5-day. Prothena Corporation plc (NASDAQ:PRTA) showed a performance of -9.19% in past 30-days. Number of shares sold short was 8.8 million shares which calculate 18.17 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 43 to the stock, which implies a rise of 69.65% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 62. It follows that stock’s current price would drop -83.91% in reaching the projected high whereas dropping to the targeted low would mean a loss of -83.91% for stock’s current value.

Prothena Corporation plc (PRTA) estimates and forecasts

Statistics highlight that Prothena Corporation plc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -41.61% of value to its shares in past 6 months, showing an annual growth rate of 18.84% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 53.83% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.53M for the same. And 3 analysts are in estimates of company making revenue of 333.33k in the next quarter. Company posted 316k and 50k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.83% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 19.77% while estimates for its earnings growth in next 5 years are of 34.07%.

Prothena Corporation plc (NASDAQ:PRTA)’s Major holders

Insiders are in possession of 13.46% of company’s total shares while institution are holding 97.30 percent of that, with stock having share float percentage of 112.44%. Investors also watch the number of corporate investors in a company very closely, which is 97.30% institutions for Prothena Corporation plc that are currently holding shares of the company. ECOR1 CAPITAL, LLC is the top institutional holder at PRTA for having 11.58 million shares of worth $239.1 million. And as of 2024-06-30, it was holding 21.5666 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 8.07 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.016 of outstanding shares, having a total worth of $166.48 million.

On the other hand, Vanguard Specialized-Health Care Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 4.5 shares of worth $58.78 million or 8.37% of the total outstanding shares. The later fund manager was in possession of 2.35 shares on Nov 30, 2024 , making its stake of worth around $30.68 million in the company or a holder of 4.37% of company’s stock.